4 Reasons Early-Phase Drug Development In The US Gives US Pharma A Competitive Edge

By Jennifer DePolo, President, General Manager and Site Head of the Siegfried Acceleration Hub

For many U.S. pharmaceutical and biotech companies, early-phase development has traditionally been outsourced overseas. However, growing pressure to accelerate timelines, reduce risk, and maintain regulatory alignment is prompting a closer look at the advantages of keeping development activities closer to home.

Domestic development can help eliminate common delays associated with international operations, including customs challenges, shipping disruptions, time zone barriers, and regulatory misalignment. These advantages become even more significant for controlled substances, where specialized registrations and approvals can directly impact development speed. Beyond timeline benefits, working within the same regulatory environment can simplify compliance, improve communication, and reduce the complexity of technology transfer as programs advance through clinical development.

Collaboration also becomes more efficient when development teams can work in real time, enabling faster decision-making and quicker resolution of technical challenges. Learn how a domestic development and manufacturing strategy can support a more streamlined path from discovery to commercialization while helping organizations maintain quality, compliance, and operational flexibility.